Compare · ANTM vs NVTA
ANTM vs NVTA
Side-by-side comparison of Anthem Inc. (ANTM) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTM and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ANTM is the larger of the two at $107.30B, about 46.4x NVTA ($2.31B).
- ANTM has more recent analyst coverage (25 ratings vs 18 for NVTA).
- Company
- Anthem Inc.
- Invitae Corporation
- Price
- $482.32+2.61%
- $0.09-77.21%
- Market cap
- $107.30B
- $2.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 25
- 18
Anthem Inc.
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Latest ANTM
- SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units
- SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units
- SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units
- SEC Form 4: Boudreaux Gail gifted 10,000 shares, decreasing direct ownership by 8% to 111,415 units
- Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4: Kendrick Charles Morgan Jr covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.54% to 14,450 units
- SEC Form 4: Haytaian Peter D covered exercise/tax liability with 200 shares, decreasing direct ownership by 2% to 11,961 units
- SEC Form 4: Strable-Soethout Deanna D was granted 200 shares
- SEC Form 3 filed by new insider Strable-Soethout Deanna D
- SEC Form 424B3 filed by Anthem Inc.
Latest NVTA
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
- Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
- Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting